Polymorphisms of neonatal Fc receptor in cynomolgus and rhesus macaques

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 5, 2014, Pages 427-430

  Uno, Yasuhiro ^a   Utoh, Masahiro ^a   Iwasaki, Kazuhide ^a  

^a SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

Cynomolgus monkey; Genetic polymorphism; mRNA expression; Neonatal Fc receptor (FcRn)

Indexed keywords

AMINO ACID; BETA 2 MICROGLOBULIN; FC RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1;

ARTICLE; B2M GENE; CAMBODIA; CHINA; CONTROLLED STUDY; FCGRT GENE; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; INDONESIA; MACACA FASCICULARIS; MALE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RHESUS MONKEY; SPECIES DIFFERENCE; TISSUE TYPING; ANIMAL; GENETICS; IMMUNOLOGY;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; MACACA FASCICULARIS; MACACA MULATTA; POLYMORPHISM, GENETIC; RECEPTORS, FC;

EID: 84908228661     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-14-NT-033     Document Type: Article

References (13)

1. Kuo, T. T. and Aveson, V. G.: Neonatal Fc receptor and IgG-based therapeutics. MAbs, 3: 422-430 (2011).
2. Roopenian, D. C. and Akilesh, S.: FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol., 7: 715-725 (2007).
3. Andersen, J. T. and Sandlie, I.: The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab. Pharmacokinet., 24: 318-332 (2009).
4. 2-microglobulin gene. Proc. Natl. Acad. Sci. USA, 103: 5084-5089 (2006).
5. Uno, Y., Fujino, H., Kito, G., Kamataki, T. and Nagata, R.: CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. Mol. Pharmacol., 70: 477-486 (2006).
6. Uno, Y., Matsushita, A., Osada, N., Uehara, S., Kohara, S., Nagata, R., Fukuzaki, K., Utoh, M., Murayama, N., et al.: Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab. Dispos., 38: 209-214 (2010).
7. Uno, Y., Sakuraba, H., Uehara, S., Kumano, T., Matsuno, K., Nakamura, C., Kito, G., Kamataki, T. and Nagata, R.: A null allele impairs function of CYP2C76 gene in cynomolgus monkeys: a possible genetic tool for generation of a better animal model in drug metabolism. Drug Metab. Dispos., 37: 14-17 (2009).
8. Ise, R., Nakanishi, Y., Kohara, S., Yamashita, H., Yoshikawa, T., Iwasaki, K., Nagata, R., Fukuzaki, K., Utoh, M., et al.: Expression profile of hepatic genes in cynomolgus macaques bred in Cambodia, China, and Indonesia: implications for cytochrome P450 genes. Drug Metab. Pharmacokinet., 27: 307-316 (2012).
9. Zhiyong, F. and Yanling, S.: Chinese primate status and primate captive breeding for biomedical research in China. In Institute for Laboratory Animal Research (eds.): International perspectives: the future of nonhuman primate resources, Washington, D. C., National Academies Press, 2002, pp. 36-45.
10. Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C. and Anderson, C. L.: The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med., 197: 315-322 (2003).
11. Ishii-Watabe, A., Saito, Y., Suzuki, T., Tada, M., Ukaji, M., Maekawa, K., Kurose, K., Kaniwa, N., Sawada, J., et al.: Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. Drug Metab. Pharmacokinet., 25: 578-587 (2010).
12. Roopenian, D. C. and Sun, V. Z.: Clinical ramifications of the MHC family Fc receptor FcRn. J. Clin. Immunol., 30: 790-797 (2010).
13. Hornby, P. J., Cooper, P. R., Kliwinski, C., Ragwan, E., Mabus, J. R., Harman, B., Thompson, S., Kauffman, A. L., Yan, Z., et al.: Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis. Pharm. Res., 31: 908-922 (2014).